Autologous cMET redirected T cells

Autologous cMET redirected T cells are a form of chimeric antigen receptor (CAR) T cell therapy in which a patient's own (autologous) T lymphocytes are genetically engineered to express a synthetic receptor targeting the c-MET protein. The most common approach uses an mRNA-modified or viral vector–engineered CAR that recognizes and binds to the hepatocyte growth factor receptor (c-MET), which is overexpressed on various tumor types including non-small cell lung cancer and breast cancer. Upon administration, these modified T cells selectively bind to and kill tumor cells expressing c-MET by inducing cytotoxicity through cytokine release and direct lysis. This strategy aims to enhance antitumor immunity by redirecting immune effector function specifically toward malignant tissue while sparing normal tissues[1][3][5]. The therapy is under investigation for solid tumors such as breast cancer and non-small cell lung cancer[3][5].

Other names

anti-cMET CAR-T cellsc-Met specific CAR-T cells